Viewing Study NCT00896051

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:50 PM
Ignite Modification Date: 2026-02-20 @ 6:45 PM
Study NCT ID: NCT00896051
Status: COMPLETED
Last Update Posted: 2013-09-30
First Post: 2009-05-07
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
Sponsor: Janssen R&D Ireland
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HIV Infections View
None Acquired Immunodeficiency Syndrome View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HIV Infections View
None Acquired Immunodeficiency Syndrome View
None TMC125-TiDP2-C238 View
None TMC125-C238 View
None Etravirine View
None Intelence View
None HIV View
None HIV-1 View
None Pharmacokinetics View